JAJafar Akbari

Jafar Akbari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jafar Akbari has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cumin Essential Oil Nanoemulgel as a Topical Analgesic and Anti-Inflammatory Alternative to NSAIDs

    by Majid Saeedi, Mohammad Eghbali, Katayoun Morteza-Semnani, Fereshteh Talebpour Amiri, Jafar Akbari, Amin Goodarzi, Seyyed Mohammad Hassan Hashemi, Amirhossein Babaei

    Cuminum cyminum L. (cumin) essential oil (CEO) possesses documented analgesic and anti-inflammatory properties, but its topical application is limited by volatility, instability and low aqueous solubility. This study aimed to develop a CEO nanoemulgel and evaluate its physicochemical characteristics, dermal safety and antinociceptive/anti-inflammatory effects in rodent models. The optimized formulation exhibited nanometric droplet size, uniform distribution and acceptable physical stability. In a rat skin irritation test, repeated application of the CEO nanoemulgel did not produce visible erythema or edema compared with the gel base. In mice, the formulation increased tail-flick latency and reduced nociceptive behaviors in both phases of the formalin test, and histological analysis revealed attenuated inflammatory cell infiltration. These findings suggest that the CEO nanoemulgel has promising antinociceptive and anti-inflammatory activity and appears to be well tolerated in short-term preclinical models. Further studies, including long-term safety assessment, mechanistic analysis and clinical trials, are required before CEO nanoemulgel can be considered for use in humans.


  • Aloe vera for Prevention of Acute Radiation Proctitis in Colorectal Cancer a Preliminary Randomized, Placebo-Controlled Clinical Trial

    by Adeleh Sahebnasagh, Fatemeh Saghafi, Arash Ghasemi, Jafar Akbari, Abbas Alipour, Solomon Habtemariam, Mohammadreza Safdari, Hassan Rezai Ghaleno, Ebrahim Salehifar

    Objective To examine the preventive effects of Aloe vera in colorectal cancer patients undergoing radiotherapy. Material and Method Twenty colorectal cancer patients, who received radiation, were randomized to receive Aloe vera 3% or placebo ointment, 1 g twice daily for 6 weeks. At weekly visits, acute radiation proctitis (ARP) was evaluated by Radiation Therapy Oncology Group and clinical presentation criteria as the primary endpoint. We also evaluated secondary endpoints of quality of life, psychosocial status, by applying Hospital Anxiety-Depression (HAD) Scale and laboratory measures of quantitative measurement of C-reactive protein (CRP) as a marker for systemic inflammation. Results There was a significant improvement in the symptom index (before treatment vs. after treatment with Aloe vera) for diarrhea (p = 0.029, median score: 0.5 vs. 0.001). The overall primary and secondary outcomes favored Aloe group, while the measures of toxicity did not achieve a statistical significant difference. The lifestyle score improved significantly with A. vera (p = 004), and they also had a lower depression score in HAD scale (p = 0.008). Furthermore, quantitative CRP decreased significantly during the course of treatment with Aloe vera. Conclusion The use of topical formulation of Aloe vera 3% diminishes the severity of ARP in colorectal cancer patients.


  • Open Access

    Prevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients

    by Adeleh Sahebnasagh, Arash Ghasemi, Jafar Akbari, Abbas Alipour, Hossein Lashkardoost, Shahram Ala, Seyed Jalal Hosseinimehr, Ebrahim Salehifar

    Background: Acute radiation-induced proctitis (ARP) is the most common side effect following radiotherapy for malignant pelvic disease. This study evaluated the efficacy of Aloe vera ointment in prevention of ARP. Methods: Forty-two patients receiving external-beam radiotherapy (RT) for pelvic malignancies were randomized to receive either Aloe vera 3% or placebo topical ointment during radiotherapy for 6 weeks. These patients were evaluated based on the severity (grade 0–4) of the following symptoms weekly: rectal bleeding, abdominal/rectal pain, diarrhea, or fecal urgency. RTOG acute toxicity criteria and psychosocial status of the patients were also recorded weekly. Lifestyle impact of the symptoms, and quantitative measurement of C-reactive protein (CRP), an indicator of systemic inflammation, were also measured. Results: The results of present study demonstrated a significant preventive effect for Aloe vera in occurrence of symptom index for diarrhea (p < 0.001), rectal bleeding (p < 0.001), and fecal urgency (p = 0.001). The median lifestyle score improved significantly with Aloe vera during RT (p < 0.001). Intervention patients had a significant lower burden of systemic inflammation as the values for quantitative CRP decreased significantly over 6 weeks of follow-up (p = 0.009). Conclusion: This study showed that Aloe vera topical ointment was effective in prevention of symptoms of ARP in patients undergoing RT for pelvic cancers. Trial registration: IRCT201606042027N6. Registration date: 2016-09-04.


  • Open Access

    The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000

    by Jafar Akbari, Majd Saeedi, Katayoun Morteza-Semnani, Hamid Reza Kelidari, Farshad Sadegh Moghanlou, Gity Zareh, Sohrab Rostamkolaei

    The Effect of Tween 20, 60, and 80 on Dissolution Behavior of Sprionolactone in Solid Dispersions Prepared by PEG 6000